

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Carprogesic 20mg Tablets for Dogs (UK, France)
Carprieve 20mg Tablets for Dogs (Germany)
Norocarp 20mg Tablets for Dogs (Belgium, Luxembourg)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Active Ingredient:

Carprofen 20 mg

Excipients:

For a full list of excipients see Section 6.1

3. PHARMACEUTICAL FORM

Tablet

A white/off white circular tablet of 8 mm diameter, 20 embossed on one side and a single breakline on the other side.

4. CLINICAL PARTICULARS

4.1 Target Species:

Dogs

4.2 Indications for Use, Specifying the Target Species:

In the dog:

Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain.

4.3 Contraindications:

Do not use in cats.

Do not use in puppies less than 4 months of age.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

Refer to section 4.7

4.4 Special Warnings for Each Target Species:

Refer to Sections 4.3 and 4.5.

4.5 Special Precautions for Use:

i. Special precautions for use in animals

Use in aged dogs may involve additional risk.

If such a use cannot be avoided, dogs may require careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.

4.6 Adverse Reactions (Frequency and Seriousness):

Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.

As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

4.7 Use During Pregnancy, Lactation or Lay:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.

4.8 Interactions with Other Medical Products and Other Forms of Interaction:

Do not administer NSAIDs and glucocorticoids concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

4.9 Amounts to be Administered and Administration Route:

For oral administration.

4mg carprofen per kg bodyweight per day.

An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.

Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.

Do not exceed the stated dose.

To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with Carprofen Tablets at 4mg/kg/day for 5 days.

4.10 Overdose (Symptoms, Emergency Procedures, Antidotes), if necessary:

Doses up to three times the recommended dosage are reported to be without adverse effect in dogs. There is no specific antidote to carprofen but general supportive therapy as applied to clinical overdosage with NSAIDs should be applied.

4.11 Withhold Period:

Not applicable.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Anti-inflammatory

ATCvet code: QM01AE91

5.1 Pharmacodynamic Properties:

Carprofen (CPF), (\pm)-6-chloro- α -methylcarbazole-2-acetic acid, is a nonsteroidal anti-inflammatory drug (NSAID). It is a derivative of phenylpropionic acid and a member of the arylpropionic acid class of NSAIDs. As a representative of the 2-arylpropionic family, it contains a chiral center at C₂ of the propionic moiety and therefore, exists in 2 stereoisomeric forms, the (+)-S and (-)-R enantiomers.

Carprofen possess anti-inflammatory, analgesic and anti-pyretic activity. Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action of carprofen is not clear.

5.2 Pharmacokinetic Properties:

Absorption is rapid with >90% absorption after oral administration. The volume of distribution is small and carprofen is highly bound to plasma proteins. Biotransformation of carprofen occurs in the liver to form the ester glucuronide and two 1-O-acyl- β -D-glucuronide diastereoisomers. These are secreted in the biliary tract and excreted in the faeces. The C_{max} is 28.51 μ g/ml and the AUC is 237.33 μ g/ml.hour

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients:

Microcrystalline Cellulose
Lactose Monohydrate
Crosscarmellose Sodium
Povidone K30
Sodium Lauril Sulphate
Magnesium Stearate

6.2 Incompatibilities:

Not Applicable.

6.3 Shelf-Life:

Shelf-life of the veterinary medicinal product as package for sale:
Tubs: 3 years
Blister strips: 2 years

6.4 Special Precautions for Storage:

Do not store above 25°C.
Store in a dry place.

6.5 Nature and Composition of Immediate Packaging:

Polypropylene tubs with white polyethylene snap secure caps.

PVC/Aluminium/Orientated polyamide blisters with aluminium lidding foil.

Pack sizes: Blisters

Box of 10 blisters, each blister contains 10 tablets.

Pack sizes: Tubs

Tub containing 100 tablets.

Not all pack sizes may be marketed.

6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials Derived From the Use of Such Products:

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements

7. MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited
Station Works
Newry
Co. Down
BT35 6JP
Northern Ireland

8. MARKETING AUTHORISATION NUMBER

Vm 02000/4248

9. DATE OF FIRST AUTHORISATION

Date: 12 April 2006

10. DATE OF REVISION OF THE TEXT

Date: October 2012